Suppr超能文献

高危早期直肠癌局部切除术后辅助放化疗而非根治性手术翻修

Adjuvant chemoradiotherapy instead of revision radical resection after local excision for high-risk early rectal cancer.

作者信息

Jeong Jae-Uk, Nam Taek-Keun, Kim Hyeong-Rok, Shim Hyun-Jeong, Kim Yong-Hyub, Yoon Mee Sun, Song Ju-Young, Ahn Sung-Ja, Chung Woong-Ki

机构信息

Department of Radiation Oncology, Chonnam National University Medical School, Hwasun-eup, Hwasun-gun, Jeonnam, South Korea.

Department of Surgery, Chonnam National University Medical School, Hwasun-eup, Hwasun-gun, Jeonnam, South Korea.

出版信息

Radiat Oncol. 2016 Sep 5;11(1):114. doi: 10.1186/s13014-016-0692-9.

Abstract

BACKGROUND

After local excision of early rectal cancer, revision radical resection is recommended for patients with high-risk pathologic stage T1 (pT1) or pT2 cancer, but the revision procedure has high morbidity rates. We evaluated the efficacy of adjuvant concurrent chemoradiotherapy (CCRT) for reducing recurrence after local excision in these patients.

METHODS

Eighty-three patients with high-risk pT1 or pT2 rectal cancer underwent postoperative adjuvant CCRT after local excision. We defined high-risk features as pT1 having tumor size ≤3 cm, and/or resection margin (RM) ≤3 mm, and/or lymphovascular invasion (LVI), and/or non-full thickness excision such as endoscopic mucosal resection (EMR) or endoscopic submucosal dissection (ESD), or unknown records regarding those features, or pT2 cancer. Radiotherapy was administered with a median dose of 50.4 Gy in 1.8 Gy fraction size over 5-7 weeks. Concurrent 5-fluorouracil and leucovorin were administered for 4 days in the first and fifth weeks of radiotherapy.

RESULTS

The median interval between local excision and radiotherapy was 34 (range, 11-104) days. Fifteen patients (18.1 %) had stage pT2 tumors, 22 (26.5 %) had RM of ≥3 mm, and 21 (25.3 %) had tumors of ≥3 cm in size. Thirteen patients (15.7 %) had LVI. Transanal excision was performed in 58 patients (69.9 %) and 25 patients (30.1 %) underwent EMR or ESD. The median follow-up was 61 months. The 5-year overall survival (OS), locoregional relapse-free survival (LRFS), and disease-free survival (DFS) rates for all patients were 94.9, 91.0, and 89.8 %, respectively. Multivariate analysis did not identify any significant factors for OS or LRFS, but the only significant factor affecting DFS was the pT stage (p = 0.027).

CONCLUSIONS

In patients with high-risk pT1 rectal cancer, adjuvant CCRT after local excision could be an effective alternative treatment instead of revision radical resection. However, patients with pT2 stage showed inferior DFS compared to pT1.

摘要

背景

早期直肠癌局部切除术后,对于病理分期为高危T1(pT1)或pT2癌的患者,建议行补救性根治性切除术,但该补救手术的发病率较高。我们评估了辅助同步放化疗(CCRT)对降低这些患者局部切除术后复发的疗效。

方法

83例高危pT1或pT2直肠癌患者在局部切除术后接受了辅助CCRT。我们将高危特征定义为:pT1肿瘤大小≤3 cm,和/或切缘(RM)≤3 mm,和/或淋巴管浸润(LVI),和/或非全层切除(如内镜黏膜切除术(EMR)或内镜黏膜下剥离术(ESD)),或关于这些特征的记录不明,或pT2癌。放疗中位剂量为50.4 Gy,分1.8 Gy每次,在5 - 7周内完成。在放疗的第1周和第5周,同步给予5 - 氟尿嘧啶和亚叶酸钙4天。

结果

局部切除与放疗的中位间隔时间为34(范围11 - 104)天。15例患者(18.1%)为pT2期肿瘤,22例(26.5%)RM≥3 mm,21例(25.3%)肿瘤大小≥3 cm。13例患者(15.7%)有LVI。58例患者(69.9%)行经肛门切除术,25例患者(30.1%)接受了EMR或ESD。中位随访时间为61个月。所有患者的5年总生存率(OS)、局部区域无复发生存率(LRFS)和无病生存率(DFS)分别为94.9%、91.0%和89.8%。多因素分析未发现影响OS或LRFS的任何显著因素,但影响DFS的唯一显著因素是pT分期(p = 0.027)。

结论

对于高危pT1直肠癌患者,局部切除术后辅助CCRT可能是替代补救性根治性切除术的有效治疗方法。然而,pT2期患者的DFS低于pT1期患者。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2c46/5011790/8455d7a0b427/13014_2016_692_Fig1_HTML.jpg

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验